5 recruiting, 4 completed, 2 active not recruiting. 8 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 5, Active not recruiting 2, Completed 1 |
| Phase 1 | 6 | Completed 3, Recruiting 3 |
| Phase 3 | 2 | Recruiting 2 |
Follow Eikon Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-11-03 |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors EIK1005, pembrolizumab (KEYTRUDA® ) - Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 160 | 2026-01-20 | 2026-10-30 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. EIK1001, Pembrolizumab (KEYTRUDA® ) - Advanced Melanoma | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 740 | 2025-05-22 | 2026-10-06 |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. EIK1004-001 (IMP1707-001) - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 130 | 2025-04-30 | 2025-08-19 |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC EIK1001, Pembrolizumab, Paclitaxel - NSCLC | Phase 2 | Active not recruiting | Eikon Therapeutics | 70 | 2024-02-06 | 2026-05-28 |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors IMP1734 - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 156 | 2023-12-11 | 2026-06-15 |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors BDB001 - Tumor, Solid | Phase 2 | Completed | Eikon Therapeutics | 1 | 2021-08-30 | 2025-11-12 |
| Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors BDB018, Pembrolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 1 | 2021-06-22 | 2025-11-12 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT - Solid Tumor, Adult, Pancreatic Cancer | Phase 2 | Active not recruiting | Institut Bergonié | 247 | 2021-03-31 | 2026-07-24 |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab BDB001 (EIK1001), Atezolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 40 | 2019-11-21 | 2025-11-12 |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab BDB001 (EIK1001), Pembrolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 87 | 2018-02-15 | 2025-11-12 |
Neoplasms (5) · Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (2) · Brain Neoplasms (1) · Endometrial Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Turcot syndrome (1) · Urinary Bladder Neoplasms (1)
pembrolizumab (6) · BDB001 (4) · Carboplatin (2) · Pemetrexed (2) · 130-nm albumin-bound paclitaxel (1) · CP protocol (1) · Cisplatin (1) · Paclitaxel (1) · atezolizumab (1)
United States (10) · Australia (5) · France (4) · South Korea (4) · Spain (4) · Austria (3) · Belgium (3) · Germany (3) · Poland (3) · Canada (2) · China (2) · Denmark (2) · Finland (2) · Italy (2) · New Zealand (2)
Harry Raftopoulos, MD (4) · Etah Kurland (1) · Etah Kurland, MD (1) · Muaz Sadeia (1) · Nilou Mobashery, MD (1) · Nishitha Reddy (1) · Viola Chen, MD (1) · Yawei Zhang, MD (1)
2019 (1), 2023 (1), 2025 (1)